![hearts of iron 4 switzerland hearts of iron 4 switzerland](https://i.ytimg.com/vi/x-xIOB6Mm_o/hqdefault.jpg)
It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. Vifor Pharma Group is a global pharmaceuticals company. The 2021 ESC guidelines are published under: About Vifor Pharma Group The ESC HF guidelines are updated periodically, with the 2021 version published at the virtual ESC congress end of August 2021. The ESC HF guidelines aim to provide practical, evidence-based recommendations for the diagnosis and treatment of HF, thereby improving and harmonizing standards of diagnosis and treatment of cardiovascular diseases for physicians, and potentially optimizing patient care. We are particularly pleased by the consideration of Ferinject ® and Veltassa ® in the new treatment guidelines to achieve these therapeutic goals and believe this will enable us to further expand our role in helping heart failure patients with iron deficiency and hyperkalemia live better, healthier lives.” Reducing the risk of heart failure hospitalizations and improving symptoms are key therapeutic goals in the treatment of heart failure. “With improved diagnosis rates of iron deficiency and enabling RAASi, more patients can benefit from treatment. “We are very pleased with the new recommendations to the ESC’s guidelines in heart failure and are grateful for this development for the patients,” commented Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma. The new proposals further describe the unique evidence for RAASi enabling generated by Veltassa ® through the clinical trials. In patients with chronic or recurrent hyperkalemia on RAAS inhibitor therapy Veltassa ® may as well be initiated to maintain the patients on guidelines recommended doses of RAAS inhibitors. The guidelines also propose that the use of potassium binder agents like Veltassa ® may allow RAAS inhibitor initiation or uptitration in a larger proportion of heart failure patients. Ferinject ® remains the only intravenous (i.v.) iron therapy specifically mentioned in the new ESC HF guidelines.
#Hearts of iron 4 switzerland update
The results of the AFFIRM-AHF study are reflected in the update of the ESC guidelines. The existing recommendation to consider Ferinject ® in patients with HF and iron deficiency to alleviate HF symptoms, improve exercise capacity and quality of life remains unchanged (Class IIa designation). Periodic screening for iron deficiency is recommended in all HF patients (Class I).įerinject ® should be considered to reduce the risk of HF hospitalizations in symptomatic HF patients with iron deficiency (Class IIa).įerinject ® should be considered before and early after discharge in patients who have been hospitalized with acute heart failure and with iron deficiency to improve HF symptoms and reduce risk of re-hospitalizations (Class IIa). With regard to iron deficiency, the following new recommendations for HF patients with reduced function of the heart are added: Vifor Pharma is pleased to announce that the European Society of Cardiology (ESC) included new recommendations and proposals in the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure for two of their key products, Ferinject ® and Veltassa ®.
GALLEN, Switzerland-( BUSINESS WIRE)-Regulatory News: